A multicenter study of cancer patients treated with anti-PD-1/PD-L1 showed that overweight and obese patients (BMI ≥ 25) experienced significantly more irAEs, particularly GI-related ones, compared to non-overweight patients (BMI < 25) (55.6% vs. 25.2%) [20,21]. Here, CD274 is linked to cancer.